Sign in
4

Changes in Ownership

Trevi Therapeutics, Inc. Filed Acc 0000950170-25-024114

Options or other derivatives

  • Chief Commercial Officer acquired 225,500 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Simon Farrell · Chief Commercial Officer

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2025-02-18 Grant or award : show line 1 in the form Stock Option (right to buy) +225,500 225,500 D
Loading xslF345X05/ownership.xml…